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Abstract
Introduction Fasting metabolite profiles have been shown to distinguish type 2 diabetes (T2D) patients from normal glucose 
tolerance (NGT) individuals.
Objectives We investigated whether, besides fasting metabolite profiles, postprandial metabolite profiles associated with 
T2D can stratify individuals with impaired fasting glucose (IFG) by their similarities to T2D.
Methods Three groups of individuals (age 45–65 years) without any history of IFG or T2D were selected from the Nether-
lands Epidemiology of Obesity study and stratified by baseline fasting glucose concentrations (NGT (n = 176), IFG (n = 186), 
T2D (n = 171)). 163 metabolites were measured under fasting and postprandial states (150 min after a meal challenge). 
Metabolite profiles specific for a high risk of T2D were identified by LASSO regression for fasting and postprandial states. 
The selected profiles were utilised to stratify IFG group into high (T2D probability ≥ 0.7) and low (T2D probability ≤ 0.5) 
risk subgroups. The stratification performances were compared with clinically relevant metabolic traits.
Results Two metabolite profiles specific for T2D  (nfasting = 12 metabolites,  npostprandial = 4 metabolites) were identified, with 
all four postprandial metabolites also being identified in the fasting state. Stratified by the postprandial profile, the high-risk 
subgroup of IFG individuals (n = 72) showed similar glucose concentrations to the low-risk subgroup (n = 57), yet a higher 
BMI (difference: 3.3 kg/m2 (95% CI 1.7–5.0)) and postprandial insulin concentrations (21.5 mU/L (95% CI 1.8–41.2)).
Conclusion Postprandial metabolites identified T2D patients as good as fasting metabolites and exhibited enhanced signals 
for IFG stratification, which offers a proof of concept that metabolomics research should not focus on the fasting state alone.
Keywords Metabolomics · Fasting · Postprandial · LASSO regularised logistic regression · Impaired fasting glucose · Risk 
stratification · Type 2 diabetes
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1 Introduction
With rapid advances in high throughput mass spectrometry-
based techniques, metabolomics is emerging as an important 
approach in clinical research for obesity and T2D (Wang 
et al. 2011; Floegel et al. 2013). To date, most metabolomics 
research is performed under fasting conditions. Nonethe-
less, studies have indicated that postprandial metabolic dis-
turbances might be novel risk factors for disease develop-
ment (Mathew et al. 2014). Therefore, using both fasting 
and postprandial metabolite measurements will extend the 
knowledge on flexibility of the human metabolome and on 
metabolic pathways involved in the initiation and progres-
sion of T2D.
Impaired fasting glycaemia (IFG) and/or impaired glu-
cose tolerance (IGT) is considered a pre-diabetic state. 
Several major clinical trials showed a reduction of T2D 
risk in the populations with IFG and/or IGT by lifestyle or 
pharmacologic interventions (Nathan et al. 2007). However, 
not all participants benefited from interventions and not all 
individuals who did not receive an intervention progressed 
to T2D, underlining the heterogeneity of the IFG/IGT group 
(Dunkley et al. 2014). These findings warrant the search for 
cost-effective risk stratification approaches to decide who to 
treat and under what circumstances. Although an abnormal 
oral-glucose tolerance test (OGTT) result is predictive for 
T2D, this test only assesses one component of metabolism, 
namely glucose metabolism. Previous longitudinal stud-
ies designed and validated a model comprised of six blood 
biomarkers to assess the 5-year risk of developing T2D 
(Kolberg et al. 2009; Urdea et al. 2009). However, very few 
studies had explored the potential of IFG stratification with 
postprandial metabolites in a drug-naïve population.
In this study, we undertook systematic analyses of 163 
blood circulating metabolites under fasting, postprandial 
states and also the responses (postprandial–fasting) between 
them. In different states, we firstly aimed to identify a subset 
of metabolites with the best classification performance to 
distinguish untreated T2D from NGT individuals. Then, we 
utilized the selected metabolite profile under fasting state 
to stratify IFG individuals according to their T2D similari-
ties as an empirical benchmark. Furthermore, the stratifica-
tion performances of postprandial and response metabolite 
profiles were compared to the stratification performance of 
fasting metabolite profile.
2  Materials and methods
2.1  Study design
The study was embedded in a population-based prospective 
cohort, the Netherlands Epidemiology of Obesity (NEO) 
study (de Mutsert et al. 2013). All participants gave written 
informed consent and the Medical Ethical Committee of the 
Leiden University Medical Center (LUMC) approved the 
study design. Initiated from 2008, men and women aged 
between 45 and 65 years with a self-reported body mass 
index (BMI) of 27 kg/m2 or higher living in the greater area 
of Leiden (in the west of the Netherlands) were eligible to 
participate in the NEO study. Participants were invited for a 
baseline visit at the NEO study center in the LUMC after an 
overnight fast. At the baseline visit, fasting blood samples 
were drawn. Within the next 5 min after the fasting blood 
draw, a liquid mixed meal (400 mL, 600 kcal, with 16% of 
energy (En%) derived from protein, 50 En% carbohydrates, 
and 34 En% fat) was consumed and subsequent blood sam-
ples were drawn 30 and 150 min after the meal.
2.2  Population and diabetes classification
From the 6671 participants included in the NEO study, 
individuals were selected (1) without a history of T2D 
or IFG and (2) without the use of any glucose- or lipid-
lowering drugs (Fig. 1). Information on diabetes status at 
baseline was verified via medical records of the general 
practitioners of the participants. A history of diabetes was 
defined as the presence of a diagnosis coded in the medical 
records with International Classification of Primary Care 
(ICPC) codes T90 (diabetes mellitus, any type), T90.1 
(type 1 diabetes mellitus) or T90.2 (type 2 diabetes mel-
litus) before the baseline study visit. A history of IFG was 
defined according to the presence of ICPC codes A91.05 
or B85.01 (both impaired glucose tolerance) in absence of 
codes T90, T90.1 or T90.2, before the baseline study visit.
The participants were further classified into three groups 
as described by the World Health Organization (Definition 
and diagnosis of diabetes mellitus and intermediate hyper-
glycemia 2006). Newly diagnosed T2D was defined as hav-
ing a fasting glucose concentration ≥ 7.0 mmol/L at the base-
line measurement without a previous history of T2D. Newly 
diagnosed IFG was defined as having a fasting glucose con-
centration ≥ 6.1 and < 7.0 mmol/L at the baseline measure-
ment without a previous history of having IFG or T2D. Par-
ticipants with a fasting glucose concentration ≤ 6.0 mmol/L 
were defined as having a normal glucose tolerance (NGT).
As an additional quality control step, we compared 
fasting glucose concentrations with fasting hexose 
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concentrations (which contains > 90% glucose). Samples 
were excluded if the fasting glucose concentration devi-
ated more than ± 1.5 standard deviation from the fasting 
hexose concentration (n = 7).
2.3  Metabolomics
Metabolomic measurements were performed in both fasting 
and postprandial (t = 150 min after the meal) EDTA-plasma 
samples at the Genome Analysis Center at the Helmholtz 
Zentrum München, Germany, using the Biocrates Abso-
luteIDQ™ p150 assay and FIA-ESI-MS/MS (flow injec-
tion-electrospray-triple quadrupol mass spectrometry) 
measurements. Due to the budget constraints and the fact 
that metabolite levels at 150 min change more significantly 
than 30 min after the meal (Krug et al. 2012), there were 
no metabolomic measurements at 30 min. The p150 assay 
includes 163 metabolites (Supplementary Table S1) from 
five substance classes: acylcarnitines (n = 41), sphingolip-
ids (n = 15), glycerophosphocholines (n = 92), amino acids 
(n = 14; 13 proteinogenic amino acids and ornithine) and 
hexoses (sum of glucose, galactose and fructose). The 
method of Biocrates AbsoluteIDQ™ p150 assay has been 
proven to be in conformance with the EMEA-Guideline 
(Guideline on bioanalytical method validation. EMEA/
CHMP/EWP/192217/2009 Rev. 1 Corr. 2 2011), which 
implies a proof of reproducibility within a given error 
range. The assay as well as the metabolite denomination 
have been described in details before (Romisch-Margl et al. 
2012). Mass spectrometric analyses were done on an API 
4000 triple quadrupole system (Sciex Deutschland GmbH, 
Darmstadt, Germany) equipped with a 1200 Series HPLC 
(Agilent Technologies Deutschland GmbH, Böblingen, 
Germany). Metabolite concentrations were calculated using 
internal standards and reported in µM. Three metabolites 
(PC aa C30:2, PC ae C38:1, SM C22:3) were dropped out 
from the analyses due to under the detection limit. Hexose 
(H1) was also not considered in the metabolite profile selec-
tion as a result of its high correlation to the fasting glucose 
concentration, leaving 159 metabolites for the analyses. The 
measurement of other blood parameters (glucose, insulin, 
HbA1c, and the lipid profile) has been described previously 
(de Mutsert et al. 2013).
2.4  Metabolite profile selection
Our preliminary step was to identify fasting, postprandial 
and response metabolite profiles, which could distinguish 
between the newly diagnosed T2D patients and NGT indi-
viduals. We used the least absolute shrinkage and selection 
operator (LASSO) method for metabolite profile selec-
tion (Supplementary information). Compared to standard 
logistic regression, LASSO method adds a constraint, i.e. it 
demands that the sum of all the parameters is smaller than 
a value λ. The selection of λ is performed through ten-fold 
cross validation (CV) by optimizing the classification per-
formance measured by area under the curve (AUC). Due 
to the restriction to value λ, some of the parameters will be 
shrunken to zero, which means the AUC is not improved 
by taking the corresponding metabolite into account. Put 
Fig. 1  Flowchart of participant 
selection from NEO study for 
the current metabolomics study
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together, the variables with non-zero estimated parameters 
form a metabolite profile.
In the fasting and postprandial states, metabolite con-
centrations were log-transformed to obtain normal distribu-
tions. Response was defined as log-transformed difference 
of metabolite concentrations between postprandial and fast-
ing state (i.e.  log[Metabolitet=150] − log[Metabolitet=0]). 
All transformed values were Z-score normalized (with a 
mean of zero and a standard deviation of one), in order to 
keep the same variance across different metabolites in the 
LASSO model. Additionally, all the selected metabolites 
were checked individually for their concentration differ-
ences between the NGT and T2D group on their original 
untransformed scales (right skewed distributions) by two-
sided Wilcoxon rank-sum tests with Bonferroni correction 
(p values < 0.05/the number of metabolites selected at least 
once in a metabolite profile) for multiple testing.
2.5  Stratification of IFG individuals
The previously selected fasting, postprandial and response 
metabolite profiles were utilised separately to stratify the 
IFG individuals into subgroups by their metabolite profile 
similarities to T2D. Assuming the stratification performance 
by fasting metabolite profile as an empirical benchmark, the 
consistency of predicted probabilities among different pran-
dial states were checked by Pearson correlation. Taking the 
left-skewed probability distributions into account, the IFG 
group was further trichotomized with the rules: (1) if the 
predicted probabilities to be T2D were ≥ 0.7 (above the aver-
age probability prediction), the individuals were classified 
as high-risk of T2D and annotated as the predicted disease 
(PD); (2) if the predicted probabilities were ≤ 0.5 (below the 
average probability prediction), the individuals were classi-
fied as low-risk of T2D and labelled as the predicted normal 
(PN); (3) for all the remaining individuals, they were classi-
fied as predicted intermediate risk (PM). Subsequently, BMI, 
HbA1c, fasting/postprandial glucose and insulin concentra-
tions, as well as HOMA-IR and HOMA-β were compared 
across the three predicted groups (predicted low, intermedi-
ate and high risk). The differences between the predicted 
three groups were tested by one-way ANOVA with Tukey 
post-hoc using PN group as the reference.
All statistical analyses were performed in R version 3.0.3. 
LASSO models were derived by R glmnet package (Fried-
man et al. 2010). Wilcoxon rank-sum tests were performed 
by wilcox.test function and ANOVA was tested by aov and 
TukeyHSD function in R stats package.
3  Results
Table 1 summarizes the baseline characteristics of all the 
participants, stratified by their fasting glucose levels into 
three groups (NGT (n = 176), IFG (n = 186), T2D (n = 171)). 
The average age was slightly younger in the NGT group than 
Table 1  Baseline characteristics 
of the study population, 
stratified by fasting glucose 
levels
Values represent mean (standard deviation), or n (%)
Normal glucose tolerance (NGT): fasting glucose ≤ 6.0 mmol/L
Impaired fasting glycaemia (IFG): fasting glucose ≥ 6.1 and < 7.0 mmol/L
Type 2 diabetes (T2D): fasting glucose ≥ 7.0 mmol/L
a For continuous variables, p values were derived from the one-way ANOVA test; for categorical variable, p 
values were derived from chi-squared test. For glucose, insulin, triglycerides, HOMA-IR and HOMA-β, the 
raw values were log-transformed before the test, in order to obtain a normal distribution
NGT (n = 175) IFG (n = 186) T2D (n = 165) p  valuesa
Demographic/anthropometric
 Age (years) 55.1 (5.6) 56.8 (5.8) 56.4 (5.5) < 0.05
 Sex (% men) 84 (48.0) 118 (63.4) 90 (54.5) < 0.05
 BMI (kg/m2) 28.3 (4.8) 30.6 (4.2) 32.6 (5.2) < 0.05
Fasting blood concentrations
 Glucose (mmol/L) 5.2 (0.5) 6.4 (0.2) 8.1 (1.8) < 0.05
 Insulin (mU/L) 11.3 (8.2) 15.4 (8.3) 22.0 (24.0) < 0.05
 HbA1c (%) 5.3 (0.2) 5.5 (0.3) 6.3 (1.1) < 0.05
 HDL-cholesterol (mmol/L) 1.5 (0.4) 1.4 (0.4) 1.2 (0.3) < 0.05
 Total cholesterol (mmol/L) 5.9 (1.1) 6.0 (1.0) 5.9 (1.1) 0.8
 Triglycerides (mmol/L) 1.2 (0.8) 1.8 (1.3) 1.9 (1.0) < 0.05
 LDL-cholesterol (mmol/L) 3.8 (1.0) 3.8 (0.9) 3.8 (1.0) 0.9
 Insulin resistance (HOMA-IR) 2.7 (2.0) 4.4 (2.4) 7.8 (8.6) < 0.05
 Beta-cell function (HOMA-β) 130.9 (90.1) 106.7 (56.4) 103.8 (111.1) < 0.05
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in the newly diagnosed IFG and T2D group. The average 
BMI was lower in the NGT group (28.3 kg/m2) than in the 
IFG and T2D group (30.6 and 32.6 kg/m2, respectively).
Under the fasting and postprandial state, the most par-
simonious profile was composed of 12 and 4 metabolites, 
respectively. The 4 metabolites selected under postprandial 
state fully overlapped with the metabolite profile under fast-
ing state (Fig. 2). The most parsimonious profile selected 
under the response comprised of 16 metabolites that were 
unique. Acylcarnitines, mainly the short-chain acylcarnitines 
accounted for over half (9 out of 16) of the metabolites in 
the response profile.
Using Wilcoxon rank-sum test and adjusting for multiple 
testing, individual metabolite concentrations were compared 
between the NGT and T2D groups. Table 2 summarizes the 
results of comparing metabolite concentrations between the 
NGT and T2D groups for the 28 metabolites selected at least 
once in a metabolite profile. In the fasting state, 9 out of 
12 metabolites showed significant differences between the 
two groups. Amongst them, the median concentration of 
C16:1 was 26.53% (95% CI [22.33, 30.83%]) higher in the 
T2D group as compared with the NGT group. In contrast, 
the median concentration of lysoPC a C17:0 was 21.06% 
(95% CI [− 15.40, − 26.29%]) lower in the T2D group than 
the NGT group. Under the postprandial state, all the four 
selected metabolites were found to discriminate the T2D 
from the NGT group, with the largest difference being for 
C16:1, which was 29.88% (95% CI [25.28, 35.07%]) higher 
in the T2D group than the NGT group. In the response pro-
file, however, unlike the fasting and postprandial states, 
only five amino acids (namely Gly, Met, Ser, Val and xLeu) 
together with C10, out of sixteen selected metabolites, were 
significantly different in the T2D group compared to the 
NGT group.
Using the selected fasting, postprandial and response 
metabolite profiles separately, 186 IFG individuals were 
stratified into three subgroups (predicted low, intermedi-
ate, and high risk to T2D) based on their metabolite profile 
similarities to T2D. Under fasting and postprandial states, 
the predicted probabilities were highly consistent (corre-
lation coefficient 0.82; 95% CI [0.76, 0.86]), and 130 out 
of 186 IFG individuals were predicted to be in the same 
risk category by two different states. Only four cases were 
assigned inconsistently from either high to low risk category 
or from low to high risk category. However, the predicted 
probabilities by response profile showed a large discrepancy 
(Fig. 3). To verify the stratification performance by differ-
ent profiles, we assessed clinically relevant metabolic traits 
within the three IFG subgroups (Fig. 4). Stratified by the 
postprandial profile composed of four metabolites alone, 
the predicted high-risk group (PD) revealed significant dif-
ference in BMI (difference = + 3.32 kg/m2, 95% CI [1.67, 
4.97]), postprandial glucose (difference = + 0.74 mmol/L, 
95% CI [0.17, 1.31]) and insulin (difference = + 21.51 mU/L, 
95% CI [1.80, 41.22]) concentrations, as well as HOMA-β 
(difference = + 23.83, 95% CI [0.44, 47.21]) compared with 
the low-risk group (PN). By the response profile (with the 
metabolite profile composed of sixteen metabolites), the 
predicted high-risk group displayed a higher fasting insu-
lin (7.21 mU/L, 95% CI [3.08, 11.33]), HOMA-IR (2.13, 
95% CI [0.93, 3.33]) and HOMA-β (46.95, 95% CI [18.73, 
75.17]) than PN group. Interestingly, for all three stratifi-
cations (by fasting, postprandial and response metabolite 
profiles separately), fasting glucose concentration was not 
shown higher levels in the predicted disease group than in 
the predicted normal group.
Fig. 2  The metabolite profiles 
selected by LASSO regularised 
logistic regression and the Venn 
diagram of the most parsi-
monious metabolite profiles 
under fasting, postprandial and 
response. The numbers high-
lighted in red colour indicate 
the number of metabolites 
composed of the profile. Full 
metabolite names are shown in 
Supplementary Table S1
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4  Discussion
Nearly all the endeavours on metabolomics research in T2D 
have focused on fasting metabolites alone. In this study, 
we found that by only four metabolites in the postprandial 
state, instead of twelve in the fasting state, could stratify 
IFG individuals with similar efficiency. Furthermore, the 
predicted T2D probabilities for the IFG individuals based 
on the selected fasting/postprandial metabolite profile were 
positively associated with other metabolic traits, such as 
higher body mass index and insulin concentration.
4.1  Discriminative metabolite profile in the fasting 
state
There is growing evidence that increased levels of plasma 
acylcarnitines are associated with the risk of T2D (Mihalik 
et al. 2010). In the current study, C16:1 and C4:1, as well as 
some other intermediate fatty acid beta-oxidation by-prod-
ucts (e.g. C8, C12) were identified under the fasting state 
and observed to be with higher concentrations in the T2D 
group compared to the NGT group. Likewise, the glucogenic 
amino acids glycine and serine can be converted into glucose 
Table 2  Results of the 
Wilcoxon rank-sum tests of 
metabolite concentration 
difference between the NGT and 
T2D groups
The original untransformed metabolite concentrations are used to test the statistical significance between 
NGT and T2D for individual metabolite
The composition of each metabolite profile selected by LASSO model is specified by “×” in the hit column
%diff reflects the percentage of metabolite concentration difference between the NGT and T2D group. It is 
calculated by taking the median of metabolite concentration differences between the NGT and T2D group 
divided by the median metabolite concentration in NGT group. The ratio multiplies by 100 to percentage
p values are calculated by two-sided Wilcoxon rank-sum tests
a p values < 1.79 × 10−3 (= 0.05/28 for Bonferroni correction) for significant difference between NGT and 
T2D group, and highlighted in bold
Metabolite Fasting Postprandial Response
Hit %diff p value hit %diff p value Hit %diff p value
C0 7.46 1.85E−03 4.19 5.25E−02 x − 2.43 2.94E−02
C10 6.54 7.17E−02 17.51 1.13E−06a x 10.28 1.51E−03a
C12 × 5.49 1.24E−01 11.10 9.54E−04a 4.54 1.06E−01
C16:1 × 26.53 1.74E−28a × 29.88 2.75E−35a 3.45 1.09E−02
C18 5.61 6.76E−02 2.59 3.77E−01 × − 3.39 6.66E−02
C2 6.85 3.70E−02 12.50 8.38E−05a × 5.71 2.94E−02
C3:1 − 4.32 6.82E−02 3.63 1.53E−01 × 6.86 2.76E−02
C4:1 × 16.40 6.01E−16a × 20.02 7.52E−16a 3.05 2.06E−01
C5 13.47 4.32E−05a 18.23 2.49E−08a × 4.68 3.60E−02
C5:1-DC 4.52 5.82E−02 10.73 8.93E−06a × 6.30 4.20E−02
C5-DC/C6-OH × − 5.13 2.34E−02 − 5.16 2.55E−02 1.61 5.66E−01
C4:1-DC/C6 9.83 8.15E−04a 7.95 1.49E−03a × − 2.66 2.35E−01
C8 × 2.47 4.18E−01 4.91 8.57E−02 1.96 4.49E−01
C9 1.58 6.54E−01 8.29 1.17E−02 × 6.49 4.06E−03
Gly × − 13.37 1.20E−08a × − 18.37 2.25E−14a − 4.80 2.11E−04a
Met 2.87 8.55E−02 − 6.77 1.03E−03a × − 10.25 1.64E−07a
Ser − 6.51 7.40E−04a − 14.97 8.02E−12a × − 9.72 6.39E−11a
Trp 3.86 1.29E−03a 3.91 5.96E−04a × 0.20 8.53E−01
Tyr × 14.94 1.93E−11a 9.29 5.56E−05a − 5.02 7.14E−03
Val − 1.69 3.62E−01 − 6.51 6.68E−04a × − 6.60 3.56E−05a
xLeu × 16.68 2.52E−11a 9.04 2.12E−04a − 6.58 1.47E−03a
lysoPC a C17:0 × − 21.06 7.50E−13a × − 21.72 7.59E−14a − 0.64 6.71E−01
lysoPC a C18:0 − 7.63 3.10E−03 − 9.42 1.04E−04a × − 2.03 1.04E−01
lysoPC a C18:1 × − 14.66 1.59E−07a − 15.35 2.98E−09a − 2.09 1.97E−01
PC aa C34:2 7.10 2.37E−05a 8.58 1.51E−07a × 1.78 8.45E−02
PC ae C30:1 6.81 1.21E−01 0.87 8.38E−01 × − 5.68 2.60E−01
PC ae C44:4 × − 8.53 4.60E−04a − 8.60 2.45E−04a − 0.37 7.52E−01
PC ae C44:5 × − 9.61 1.94E−04a − 11.05 2.79E−05a − 1.55 1.12E−01
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by gluconeogenesis, predominantly in the fasting state. In 
our study, the concentration of glycine was significantly 
decreased among the T2D individuals compared to the 
NGT group and selected by the LASSO model. This find-
ing further supports the hypothesis that with the develop-
ment of T2D, insulin exerts a decreased inhibitory effect on 
hepatic gluconeogenesis and as a result leads to an increased 
demand and consumption of glucogenic amino acids (Ren-
ner et al. 2012). Additionally, consistent with the previous 
findings, plasma lysophosphatidylcholines (e.g. lysoPC a 
18:0, lysoPC a 18:1 and lysoPC a 18:2) (Barber et al. 2012) 
were inversely associated with the T2D risk. However, the 
selection of the lysophosphatidylcholines (lysoPC a C17:0 
and lysoPC a C18:1) in the present metabolite profile might 
be due to the difference in adiposity rather than diabetes 
status per se (Barber et al. 2012) as BMI was also observed 
to be higher in the T2D group than the NGT group in the 
current study population. Although common confounders, 
Fig. 3  The distributions of T2D probability prediction for the IFG group under fasting, postprandial and response and the probability correla-
tions between different states. The Pearson correlations were labeled on the top of the figure
Fig. 4  The distributions of clinically relevant metabolic traits across 
three subgroups (PN predicted normal, PM predicted middle, PD pre-
dicted T2D) in the IFG group predicted by LASSO model, along with 
the NGT and T2D group. Differences between PN, PM and PD were 
statistically depicted by one-way ANOVA with Tukey post hoc from 
PN as the reference group. *p value < 0.05
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such as BMI in the current study, are generally not taken into 
consideration in the prediction research (van Diepen et al. 
2017), oversampling on the overweighed and obese popu-
lation in the current study may hinder the generalizability 
of the findings. However, after regressing out age, sex and 
BMI from the metabolite concentrations, we still observed 
very similar results regarding IFG predictions under differ-
ent states (data not shown).
4.2  Discriminating metabolites in the postprandial 
and response states
For the postprandial state, a profile consisting of only four 
metabolites could distinguish the TD2 group from the NGT 
group. Thus, a controlled meal challenge greatly enhanced 
the metabolite signals to separate the T2D from the NGT 
individuals. The fact that the four metabolites are able to dif-
ferentiate in a non-fasting state provides proof of concept for 
the potential clinical usefulness of non-fasting metabolites 
as biomarkers.
It is important to note that > 50% of the T2D-specific 
metabolites from the response were acylcarnitines, and 
more specifically short-chain acylcarnitines. Acetylcar-
nitine (C2), the shortest acylcarnitine, has been identified 
as one of the fasting state biomarkers for diagnosis of pre-
diabetes (Wang-Sattler et al. 2012). It was described to be 
involved in substrate selection and promotion of metabolic 
flexibility (Schooneman et al. 2013). However, we did not 
observe a significant difference in the fasting C2 concen-
tration between the NGT and T2D group from the present 
dataset. In contrast, a significant C2 concentration increase 
was found in the postprandial state.
4.3  Stratification IFG individuals by metabolite 
profile similarity to T2D
By taking stratification performance of fasting metabolite 
profile as an empirical benchmark, 130 out of 186 IFG indi-
viduals were assigned to the same risk categories by the 
postprandial metabolite profile. Of the remaining 56 “mis-
classified” individuals, only three cases were predicted to 
be low-risk by applying the postprandial metabolite profile, 
which were assigned as high risk by the fasting metabolite 
profile. In a clinical setting, only the predicted high-risk 
individuals would be taken into account for an intervention 
program. So compared to the fasting metabolite profile, the 
postprandial metabolite profile achieved a very similar risk 
stratification. The categories for NGT, IFG and T2D were 
defined by the fasting glucose measurements at baseline. 
However, in the subgroups of the IFG individuals strati-
fied by the selected metabolite profiles, we were unable 
to observe a clear distinction based on the fasting glucose 
levels. Nevertheless, there was a clear distinction in the 
fasting and postprandial insulin concentrations across three 
subgroups in the IFG stages, stratified by different profiles. 
So insulin levels might be more sensitive than the fasting 
glucose levels to evaluate the progression of disease with 
respect to glucose and lipid metabolism, especially in the 
pre-diabetic stage. For the other clinically relevant glycae-
mic traits, such as HbA1c, HOMA-IR, HOMA-β, the high-
risk subgroup also displayed increased levels compared to 
the low-risk subgroup, which further confirmed the effec-
tiveness of metabolite profiles in the IFG stratification.
4.4  Methodological considerations
Some methodological issues should be considered. Firstly, 
a major strength of the current study is that all partici-
pants were naïve to drug treatment. In most cross-sectional 
metabolomics studies on T2D, the participants were using 
glucose- or lipid-lowering drugs, which could influence the 
results (Altmaier et al. 2014). Secondly, many metabolomics 
studies on T2D confirm the diagnosis based on questionnaire 
or by a physician. We defined newly diagnosed T2D by the 
fasting glucose levels. Unfortunately, we only had a single 
measurement and no oral glucose tolerance test as is recom-
mended by the World Health Organization. Therefore, there 
may be some misclassification in the diabetes classification. 
The main limitation is related to our cross-sectional study 
design. In this analysis, we could not affirm whether the pre-
dicted high-risk subgroup in IFG had a larger proportion of 
individuals developing to T2D than the low-risk subgroup. 
Besides, due to our definition, we are unable to investigate 
patients with IGT. Subsequently, we cannot extrapolate our 
results to the entire pre-diabetic population at risk of devel-
oping T2D.
5  Conclusion
In conclusion, postprandial metabolite profiles revealed 
enhanced signals to distinguish the NGT and T2D individu-
als and provided a very similar IFG stratification scheme as 
the fasting metabolite profile, which offers a proof of con-
cept that metabolomics research on type 2 diabetes should 
not be focused on the fasting state alone. Follow-up stud-
ies, such as in the NEO study, will allow us to investigate 
whether predicted high-risk IFG individuals truly develop 
to the disease.
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